Triple-Negative Breast Cancer (TNBC) Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Triple-negative Breast Cancer

IndicationStatusPhase
DBCOND0067309 (Triple-Negative Breast Cancer (TNBC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04024800Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerTreatment
NCT03639948Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerTreatment